JP7617030B2 - Ｊａｋ阻害剤 - Google Patents

Ｊａｋ阻害剤 Download PDF

Info

Publication number
JP7617030B2
JP7617030B2 JP2021566284A JP2021566284A JP7617030B2 JP 7617030 B2 JP7617030 B2 JP 7617030B2 JP 2021566284 A JP2021566284 A JP 2021566284A JP 2021566284 A JP2021566284 A JP 2021566284A JP 7617030 B2 JP7617030 B2 JP 7617030B2
Authority
JP
Japan
Prior art keywords
pharma
formula
ceutically acceptable
solvate
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021566284A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020227563A5 (https=
JP2022532877A (ja
JP2022532877A5 (https=
Inventor
モハン，ラジュ
ナス，ジョン
ハリス，ジェイソン
ユアン，シェンドン
Original Assignee
ビマラン バイオサイエンシーズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビマラン バイオサイエンシーズ，インク． filed Critical ビマラン バイオサイエンシーズ，インク．
Publication of JP2022532877A publication Critical patent/JP2022532877A/ja
Publication of JPWO2020227563A5 publication Critical patent/JPWO2020227563A5/ja
Publication of JP2022532877A5 publication Critical patent/JP2022532877A5/ja
Application granted granted Critical
Publication of JP7617030B2 publication Critical patent/JP7617030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
JP2021566284A 2019-05-08 2020-05-07 Ｊａｋ阻害剤 Active JP7617030B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962845119P 2019-05-08 2019-05-08
US62/845,119 2019-05-08
US201962884588P 2019-08-08 2019-08-08
US62/884,588 2019-08-08
PCT/US2020/031925 WO2020227563A1 (en) 2019-05-08 2020-05-07 Jak inhibitors

Publications (4)

Publication Number Publication Date
JP2022532877A JP2022532877A (ja) 2022-07-20
JPWO2020227563A5 JPWO2020227563A5 (https=) 2023-05-16
JP2022532877A5 JP2022532877A5 (https=) 2023-05-16
JP7617030B2 true JP7617030B2 (ja) 2025-01-17

Family

ID=73051620

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566284A Active JP7617030B2 (ja) 2019-05-08 2020-05-07 Ｊａｋ阻害剤

Country Status (13)

Country Link
US (1) US11136329B2 (https=)
EP (1) EP3966209A4 (https=)
JP (1) JP7617030B2 (https=)
KR (1) KR102916168B1 (https=)
CN (1) CN114269734B (https=)
AU (1) AU2020267661A1 (https=)
BR (1) BR112021022380A2 (https=)
CA (1) CA3139277A1 (https=)
IL (1) IL287876A (https=)
MX (1) MX2021013602A (https=)
SG (1) SG11202112362YA (https=)
TW (1) TWI865525B (https=)
WO (1) WO2020227563A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7617030B2 (ja) 2019-05-08 2025-01-17 ビマラン バイオサイエンシーズ，インク． Ｊａｋ阻害剤
KR20220051351A (ko) 2019-08-08 2022-04-26 비말란 바이오사이언스즈, 인크. Jak 억제제
CN114644633B (zh) * 2020-12-18 2026-02-03 北京诺诚健华医药科技有限公司 杂环类jak抑制剂
KR102637915B1 (ko) * 2021-06-25 2024-02-19 한국화학연구원 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538341A (ja) 2006-05-26 2009-11-05 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン化合物およびそれらの使用
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
JP2013508332A (ja) 2009-10-20 2013-03-07 セルゾーム リミティッド Ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
JP2013525392A (ja) 2010-04-30 2013-06-20 セルゾーム リミティッド Ｊａｋ阻害剤としてのピラゾール化合物
WO2016208595A1 (ja) 2015-06-22 2016-12-29 小野薬品工業株式会社 Ｂｒｋ阻害化合物
JP2022544174A (ja) 2019-08-08 2022-10-17 ビマラン バイオサイエンシーズ，インク． Ｊａｋ阻害剤
JP2022549435A (ja) 2019-09-25 2022-11-25 ビマラン バイオサイエンシーズ，インク． Ｊａｋ阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200802685B (en) 2005-09-30 2009-10-28 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
EP2108019A2 (en) 2007-01-30 2009-10-14 Biogen Idec MA, Inc. 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases
UY31631A1 (es) 2008-02-06 2009-09-30 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
WO2013041605A1 (en) * 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
WO2014001973A1 (en) 2012-06-29 2014-01-03 Pfizer Inc. NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
CN108864057B (zh) * 2017-05-16 2020-03-31 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
JP7617030B2 (ja) 2019-05-08 2025-01-17 ビマラン バイオサイエンシーズ，インク． Ｊａｋ阻害剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538341A (ja) 2006-05-26 2009-11-05 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン化合物およびそれらの使用
JP2013508332A (ja) 2009-10-20 2013-03-07 セルゾーム リミティッド Ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
JP2013525392A (ja) 2010-04-30 2013-06-20 セルゾーム リミティッド Ｊａｋ阻害剤としてのピラゾール化合物
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
WO2016208595A1 (ja) 2015-06-22 2016-12-29 小野薬品工業株式会社 Ｂｒｋ阻害化合物
JP2022544174A (ja) 2019-08-08 2022-10-17 ビマラン バイオサイエンシーズ，インク． Ｊａｋ阻害剤
JP2022549435A (ja) 2019-09-25 2022-11-25 ビマラン バイオサイエンシーズ，インク． Ｊａｋ阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C.G.WERMUTH編，『最新 創薬化学 上巻』，株式会社テクノミック，1998年08月15日，235-271頁，13章 等価置換に基づく分子の変換
野崎正勝 等，創薬化学，第１版，株式会社化学同人，1995年，p.98-99

Also Published As

Publication number Publication date
EP3966209A4 (en) 2023-01-04
CN114269734B (zh) 2026-03-27
TWI865525B (zh) 2024-12-11
KR102916168B1 (ko) 2026-01-21
BR112021022380A2 (pt) 2022-03-22
JP2022532877A (ja) 2022-07-20
CA3139277A1 (en) 2020-11-12
EP3966209A1 (en) 2022-03-16
MX2021013602A (es) 2022-04-06
TW202108587A (zh) 2021-03-01
KR20220052859A (ko) 2022-04-28
IL287876A (en) 2022-01-01
CN114269734A (zh) 2022-04-01
WO2020227563A1 (en) 2020-11-12
US20200369669A1 (en) 2020-11-26
SG11202112362YA (en) 2021-12-30
AU2020267661A1 (en) 2021-12-23
US11136329B2 (en) 2021-10-05

Similar Documents

Publication Publication Date Title
JP7635228B2 (ja) Ｔｙｋ２偽キナーゼリガンド
JP7617030B2 (ja) Ｊａｋ阻害剤
JP7595582B2 (ja) Ｔｙｋ２偽キナーゼリガンド
EP3920931A1 (en) Tyk2 pseudokinase ligands
JP2022549435A (ja) Ｊａｋ阻害剤
US11459333B2 (en) Substituted pyrrolo[2,3-d]pyrimidines as JAK inhibitors
HK40080624A (en) Jak inhibitors
HK40072097A (en) Jak inhibitors
HK40080028B (zh) Tyk2假激酶配体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250106

R150 Certificate of patent or registration of utility model

Ref document number: 7617030

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150